Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hepatocyte cell therapy (Heparesc) - Cellaion

Drug Profile

Hepatocyte cell therapy (Heparesc) - Cellaion

Alternative Names: Heparesc; HHLivC; Human heterologous liver cells for infusion

Latest Information Update: 17 Feb 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytonet
  • Developer Cellaion; Cytonet; Promethera Biosciences
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn urea cycle disorders; Liver failure
  • New Molecular Entity No
  • Available For Licensing Yes - Inborn urea cycle disorders

Highest Development Phases

  • Preregistration Inborn urea cycle disorders
  • Phase II/III Liver failure

Most Recent Events

  • 29 Aug 2018 Hepatocyte cell therapy (Heparesc) - Promethera Biosciences is available for licensing in Canada as of 16 Jan 2020. www.promethera.com
  • 05 Oct 2017 Promethera Biosciences and Shibuya enter into collaboration to develop manufacturing platform for stem cell therapies for treatment of liver disorders
  • 03 Jul 2017 Preregistration for Inborn urea cycle disorders (In children, In infants, In neonates) in Canada prior to July 2017 (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top